Author:
CHEN Min-jiang,ZHONG Wei,ZHANG Li,ZHAO Jing,LI Long-yun,WANG Meng-zhao
Abstract
Background
Gefitinib is widely used in the treatment of advanced non-small cell lung cancer (NSCLC). However, only a small number of reports have described initial failure sites in patients treated with gefitinib. The aim of this study was to investigate survival, recurrence sites, and treatment after recurrence in these patients.
Methods
A retrospective review was conducted of all patients with stage III/IV NSCLC treated with gefitinib in Peking Union Medical College Hospital from October 2002 to September 2011. Patient characteristics, initial failure sites, associated clinical factors, and subsequent therapy were included in the analysis of prognostic factors.
Results
A total of 316 patients were identified The median progress free survival (PFS) and overall survival (OS) times were 238 days and 468 days, respectively. The median survival time after progression was 145 days. The sites of initial failure were lung (62.34%), bone (17.72%), central nerve system (CNS, 16.14%), liver (9.49%), and others (7.19%). Patients with single-site progression or multi-site progression were 81.01% and 18.99%, respectively. Progression-free survival time was associated with lung and bone failure. Additionally, the median survival time after progression was lower in patients with multi-site progression and liver progression. Other initial failure sites displayed no relationship with survival, including CNS failure. Subsequent therapy may affect survival after progression. In patients receiving continuous epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy, chemotherapy, radiotherapy, and re-treatment with EGFR-TKIs, survival time after progression was prolonged compared with the best supportive care.
Conclusions
Our data suggest that patients receiving gefitinib should be closely monitored regarding lung metastasis during follow-up. Liver metastases and multi-site progression were poor prognostic factors. After failure with gefitinib, patients may benefit from radiotherapy, chemotherapy, continuous EGFR-TKI therapy and re-treatment with EGFR-TKIs.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference27 articles.
1. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.;Molina;Mayo Clin Proc,2008
2. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.;Therasse;J Natl Cancer Inst,2000
3. Survival analysis of 1742 patients with stage IV non-small cell lung cancer.;Peng;Chin J Lung Cancer (Chin),2011
4. Skeletal metastases in non-small cell lung cancer: a retrospective study.;Tsuya;Lung Cancer,2007
5. Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292.;Furugaki;Clin Exp Metastasis,2011
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献